Compare ESCA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | IKT |
|---|---|---|
| Founded | 1922 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2M | 220.5M |
| IPO Year | 1995 | 2020 |
| Metric | ESCA | IKT |
|---|---|---|
| Price | $20.13 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 44.0K | ★ 755.7K |
| Earning Date | 04-30-2026 | 03-26-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | 6.45 | ★ 57.76 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.82 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $1.33 |
| 52 Week High | $23.07 | $2.53 |
| Indicator | ESCA | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 62.29 |
| Support Level | $17.63 | $1.63 |
| Resistance Level | $21.32 | $2.53 |
| Average True Range (ATR) | 1.12 | 0.13 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 36.53 | 73.42 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.